Angara Bio

Drugging RNA-binding proteins with precision chemistry.

UT Seed Fund Portco
HQ Region Boston, MA

Angara Bio is a discovery-stage biotechnology company developing small-molecule therapeutics targeting RNA-binding proteins (RBPs) - central regulators of gene expression with established roles in disease but have remained largely undruggable. Building on foundational research by scientific founder Ken Hsu (UT Austin), published in Nature Communications, Angara’s proprietary live-cell chemoproteomics platform uncovers functionally relevant, ligandable sites within RNA–protein complexes, creating new opportunities for small-molecule drug discovery.

Angara’s lead program in myotonic dystrophy type 1 (DM1) aims to restore normal RNA splicing by releasing a key splicing regulator from toxic repeat RNA. The company is leveraging its platform to develop additional therapeutics targeting disease-driving RBPs across multiple indications.

UT Seed Fund 2024
Status Active
Founders
Yelena Wetherill | Co-Founder & CEO | Biotech executive. Previously Venture Fellow and Entrepreneur-in-Residence at SANTÉ, and Director of Alliance Management, Business Development & Licensing at the Novartis Institutes for BioMedical Research. | https://www.linkedin.com/in/yelena-wetherill-16904ab/ | https://sante.com/wp-content/uploads/2023/10/Yelena_candid_color.jpg Ku-Lung (Ken) Hsu, PhD | Scientific Founder | Associate Professor of Chemistry and CPRIT Scholar at UT Austin, where his lab builds covalent small molecules to probe human biology and disease. Previously on the chemistry faculty at the University of Virginia; PhD from UT Austin, postdoctoral training at The Scripps Research Institute. | https://www.linkedin.com/in/ku-lung-hsu-794b0ba6/ | https://hsulab.com/site-images/ku-lung-ken-hsu-futurebiochem_orig.jpg
Secondary sectors RNA-Binding Proteins, Small Molecules, Chemoproteomics